Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio-B) disclosed a share repurchase on 13 April 2026, acquiring 66,300 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 7.04 and HKD 7.05 per share. The transaction, executed under the company’s June 2025 buyback mandate, cost HKD 0.47 million and carried a volume-weighted average price of HKD 7.0474 per share.

Following the purchase, Jacobio’s outstanding share capital (excluding treasury shares) fell marginally by 0.0084 % to 785.73 million shares, while treasury shares rose to 6.02 million. Total issued shares remained unchanged at 791.76 million.

Since the mandate began, the company has repurchased 3.00 million shares, equivalent to 0.38 % of the issued share base at the mandate’s adoption date. Jacobio is restricted from issuing new shares or selling treasury shares until 13 May 2026 under Hong Kong Stock Exchange rules governing post-buyback activities.